<DOC>
	<DOCNO>NCT01145313</DOCNO>
	<brief_summary>The primary objective examine change pre/post-augmentation healthcare cost resource utilization patient diagnose major depressive disorder ( MDD ) augment current antidepressant therapy atypical antipsychotic .</brief_summary>
	<brief_title>Impact Atypical Antipsychotic Therapy Health Outcomes Costs Among Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients meet follow criterion include study : age 18 64 year diagnosis major depressive disorder study timeframe ( ICD 9 code 296.2 , 296.3 , 311 ) evidence least 6 consecutive claim traditional antidepressant therapy 30 day supply least 2 claim 90 day supply ( consecutive define ≤15 day gap ) must continually enrol study timeframe medical pharmacy benefit evidence least 4 consecutive claim atypical antipsychotic prescription 30 day supply 2 claim 90 day supply ( consecutive define ≤15 day gap ) evidence antidepressant therapy least 60 consecutive day prior initiation atypical antipsychotic After least 60 day trial traditional antidepressant medication , patient augments atypical antipsychotic medication least 4 month . Patients exclude : claim diagnosis schizophrenia , schizoaffective bipolar disorder study period Electroconvulsive therapy ( ECT ) study period new augmentation mood stabilizer , Lthyroxine ( T4 ) , LThyronine ( T3 ) , buspirone , stimulant , others postperiod ( table 1 ) pregnant study period patient Medicare Medicaid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>